

DAFTAR PUSTAKA

- Ai, Xiaoye.,Yasheng,Adalati., Zhangjia, Zhennan., Tong,Ying., Zhao, Bing. 2018. Study of the relationship between EGFR mutation status and bone metastasis in advanced lung adenocarcinoma. Biomedical Research. 10.4066/biomedicalresearch.29-17-1489.
- Agustina, T.S., Wulandari, L. 2017 Perbandingan Respons Terapi Gefitinib pada Pasien KPKBSK EGFR Mutasi Exon 19 dan Exon 21.*J Respir Indo.*; 37: 232-40
- Amin, Z.2014. Kanker Paru. Dalam: Sudoyo, A.W., Setryohadi, B., Alwi, I.Simadibrata, M.K., Setiati, S. Ilmu Penyakit Dalam .Ed 6. Jakarta: Pusat Penerbitan Departemen Ilmu Penyakit Dalam Fakultas Kedokteran Universitas Indonesia.
- Bethune, G., Bethune, D., Ridgway, N., Xu, Z. 2010. Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update. *J Thorac Dis*; 2: 48-51
- Cabanero, M., Sangha, R., Sheffield, B.S., Sukhai, M., Pakkal, M., Kamel-Reid, S., Karsan.,Ionescu, D., Juergens, R.A., Butts, C., Tsao, M.S. 2017. Management of EGFR-mutated non-small-cell lung cancer: practical implications from a clinical and pathology perspective. *CurrOncol.* Apr;24(2):111-119
- Cetin K., Ettinger DS., Hei YJ., O'Malley CD. 2011. Survival by histologic subtype in stage IV nonsmall cell lung cancer based on data from the Surveillance, Epidemiology and End Results Program. *Clin Epidemiol.* 2011;3:139-148.
- Chao, P. I., Gregory, C., Lunqing, Z., Long, L. I., Tou, C. H., Hong, C. T., 2017. Retrospective analysis of Gefitinib and Erlotinib in EGFR-mutated non-small-cell lung cancer patients.*Journal of Lung Health and Disease.* 1(1):16–24.
- Cheema, P.K., Burkes, R.L. 2013.Overall survival should be the primary endpoint inclinical trials for advanced non-small-cell lung cancer. *CurrOncol*, Vol. 20, pp. e150-160
- Chi A, Remick S, Tse W. EGFR inhibition in non-small cell lung cancer: current evidence and future directions. *Biomark Res.* 2013;1:2

- Cho, K.M., Keam, B., Kim, T.M., Lee, S.H., Kim, D.W., Heo, D.S. 2015. Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure. *Korean J Intern Med*;30:891-898
- Citri, A, Yarden, Y. 2006 .EGF-ERBB signalling: towards the systems level. *Nat Rev Mol Cell Biol*. Jul; 7(7):505–516. [PubMed: 16829981]
- Crabtree, T.D., Denlinger, C.E., Meyers, B.F, et al. 2010. Stereotactic body radiation therapy versus surgical resection for stage I non-small cell lung cancer. *J ThoracCardiovasc Surg*;140:377-386
- Decaluwé, H., De Leyn, P., Vansteenkiste, J., et al. 2009. Surgical multimodality treatment for baseline resectable stage IIIA-N2 non-small cell lung cancer. Degree of mediastinal lymph node involvement and impact on survival. *Eur J CardiothoracSurg*; 36:433-439.
- Eberhardt, W., De Ruysscher, D., Weder, W. 2015. ESMO consensus guidelines: locally advanced stage III non-small-cell lung cancer (NSCLC). *Ann of Oncol*: 26 (8): 1573-1588
- Ettinger, D.S., Wood, D.E., Aisner, D.L., Akerley, W., Bauman, J., Chirieac, E.L, et al. 2015. Non-small cell lung cancer version 3. *J NatlComprCanc Netw*.;13:515-24
- Fan, W. C., Yu, C. J., Tsai, C. M., Huang, M. S., Lai, C. L., Hsia, T. C., Tien, Y. J., Huang, S. F., Wu, C. H., Chou, K. T., Lee, Y. C., Perng, R. P., & Chen, Y. M. 2011. Different efficacies of erlotinib and gefitinib in taiwanese patients with advanced non-small cell lung cancer: a retrospective multicenter study. *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*, 6(1), 148–155.
- Farjah, F., Flum, D.R., Varghese, T.K, Jr., et al. 2009. Surgeon specialty and long-term survival after pulmonary resection for lung cancer. *Ann ThoracSurg*; 87:995-1006.
- Fenchel, K., Sellmann, L., Dempke, W.C.M. 2016. Overall survival in non-small cell lung cancer—what is clinically meaningful? *Transl Lung Cancer Res*;5(1):115-119
- Früh, M., De Ruysscher, D., Popat, S., Crinò, L., Peters, S., Felip, E. 2013. ESMO Guidelines Working Group. Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. Oct;24Suppl 6:vi99-105

- Grills, I.S, Mangona, V.S, Welsh R, et al. 2010. Outcomes After Stereotactic Lung Radiotherapy or Wedge Resection for Stage I Non-Small-Cell Lung Cancer. *J ClinOncol*; 28:928-935.
- Hsu, F., De Caluwe, A., Anderson, D., Nichol, A., Toriumi, T., & Ho, C. (2017). Patterns of spread and prognostic implications of lung cancer metastasis in an era of driver mutations. *Current oncology (Toronto, Ont.)*, 24(4), 228–233.
- Howington, J.A, Blum, M.G., Chang, A.C, et al. 2013. Treatment of stage I and II non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest*. May;143(5 Suppl):e278S-313S
- Hynes, N.E, Lane, H.A. ERBB receptors and cancer: the complexity of targeted inhibitors. *Nat RevCancer*. 2005 May; 5(5):341–354.
- Jett, J.R., Schild, S.E., Kesler, K.A., Kalemkerian, G.P. 2013. Treatment of small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest*. May;143(5 Suppl):e400S-19S.
- J. C. Soria, C. Massard, T. Le Chevalier; Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy, *Annals of Oncology*, Volume 21, Issue 12, 1 December 2010, Pages 2324–2332.
- Kelsey, C.R., Light, K.L, Marks, L.B. 2006. Patterns of failure after resection of non-small-cell lung cancer: implications for postoperative radiation therapy volumes. *Int J RadiatOncolBiolPhys*; 65:1097-1105.
- Kementrian Kesehatan RI. 2008. Riset Kesehatan Dasar tahun 2007. Jakarta.
- Krawczyk, P., Kowalski, D. M., Ramlau, R., Kalinka-Warzocha, E., Winiarczyk, K., Stencel, K., et al. 2017. Comparison of the effectiveness of erlotinib, gefitinib, and afatinib for treatment of non small cell lung cancer in patients with common and rare EGFR gene mutations. *Oncology Letters*. 13(7):4433–4444
- Kris, M.G., Natale, R.B., Herbst, R.S., et al. 2003. Efficacy of gefitinib, an inhibitor of the epidermal growthfactor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. *JAMA*; 290(16):2149–2158.
- Kwak, EL., Bang, YJ., Camidge, DR., et al. 2010. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. *N Engl J Med*, 361, 1693-703.

- Lally, B.E., Zelterman, D., Colasanto, J.M, et al. 2006. Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the surveillance, epidemiology, and end results database. *J Clin Oncol*;24:2998-3006.
- Levitzki, A., Mishani, E.2006. Tyrophostins and other tyrosine kinase inhibitors.*Annu Rev Biochem.* 75: 93–109.
- Lim, S. H., Lee, J. Y., Sun, Jong-Mu., Ahn, J. S., Park, K., Ahn, Myung-Ju., 2014. Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non – Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor Receptor Mutation.*Journal of Thoracic Oncology.* 9(4):506–511.
- Lin, J.J., Cardarella, S., Lydon, C.A., Dahlberg, S.E., Jackman, D.M., Jänne, P.A., Johnson, B.E. 2016 . Five-year survival in EGFR-mutant metastatic lung adenocarcinoma treated with EGFR-TKIs. *J ThoracOncol.* April ; 11(4): 556–565.
- Linardou H, Briasoulis E, Dahabreh IJ, Mountzios G, Papadimitriou C, Papadopoulos S, Bafaloukos D, Kosmidis P, Murray S. 2011. All about KRAS for clinical oncology practice: Gene profile, clinical implications and laboratory recommendations for somatic mutational testing in colorectal cancer. *Cancer Treat Rev* 37:221-233
- Melindawati, Y. 2008. Karakteristik Penderita Kanker Paru Rawat Inap Di RSUP H. Adam Malik Medan Tahun 2004-2008. Tesis.Universitas Sumatra Utara. Medan.
- Memo-inOncology. Lung Cancer International Preceptroship. Springer-Verlag Gmbh. German.2018
- Molina, J.R., Yang, P., Cassivi, S.D., Schild, S.E., Adjei, A.A. 2008. Non–Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship. *Mayo Clin Proc.* May ; 83(5): 584–594.
- Nakahama, K., Tamiya, A., Taniguchi, Y., Naoki, Y., Kanazu, M., Atagi, S.2017. Comparing Gefitinib and Erlotinib With Regard To Brain Metastases Recurrence in EGFR-Mutant Non-Small Cell Lung Cancer Patients. *J ClinExpOncol* 6:4.
- NCCN. 2018. Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Version 4.2018.

- Onishi H, Shirato H, Nagata Y, et al. 2011. Stereotactic body radiotherapy (SBRT) for operable stage I non-small-cell lung cancer: can SBRT be comparable to surgery? *Int J Radiat Oncol Biol Phys*;81:1352-1358.
- Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., *et al.*, 2005. Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain. *Plos Medicine*, 2(3):0225–0235
- Perez-Soler, R. 2004. Phase II clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) in non-small-cell lung cancer. *Clin Lung Cancer*. Dec; 6(Suppl1):S20–S23.
- Planchard, D, Popat, S, Kerr, K, Novello, S, Smit, E.F., Faivre- Finn, C, *et al.* 2018. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2018 Oct 1;29(Supplement_4):iv192-iv237
- Ramnath, N., Dilling, T.J., Harris, L.J., et al. 2013. Treatment of stage III non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest*. May;143(5 Suppl):e314S-40S.
- Reckamp, KL. 2016. Lung Cancer Treatment and Research. Switzerland: Springer International Publishing.
- Reck, M., Popat, S., Reinmuth, N., et al. 2014. Clinical practice guidelines: metastatic non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Annals of Oncology*; 25 (suppl 3): iii27-iii39.
- Ridge, CA., McErlean, A.M., Ginsberg, M.S. 2013. Epidemiology of Lung Cancer. *Semin Intervent Radiol*;30:93–98.
- Riely GJ, Jenifer M, William P. 2009. KRAS Mutations in Non–Small Cell Lung Cancer. *Proc Am Thorac Soc* 6:201–20.
- Rivera, P.M., Mehta, A.C., Wahidi, M.M. 2014. Diagnosis and management of lung cancer, 3rd ed: American college of physicians evidence-based clinical practice guidelines. *Chest*; 143(5): 142 – 165.
- Santos GC, Shepherd FA, Tsao MS. 2011. EGFR mutation and lung cancer. *Annu Rev Pathol Mech Dis* 6:49-69.
- Scagliotti, G.V, Parikh, P., von Pawel, J., et al. 2008. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in

chemotherapy-naïve patients with advanced-stage non-small-cell lung cancer. *J ClinOncol.* 26:3543–3551.

Schwartz, L.H., Litière, S., de Vries, E., et al., 2016. RECIST 1.1 – Update and Clarification: From the RECIST Committee. *Eur J Cancer.* 2016 Jul; 62: 132–137.

Sharma, S. V., Bell, D. W., Settleman, J., Haber, D. A., 2007. Epidermal growth factor receptor mutations in lung cancer. *Nature Review Cancer.* 7(March):169–181.

Sher, D.J., Fidler, M.J., Liptay, M.J., Koshy, M. 2015. Comparative effectiveness of neoadjuvantchemoradiotherapy versus chemotherapy alone followed by surgery for patients with stage IIIA non-small cell lung cancer. *Lancet Oncol;* 88:267-274.

Shaw, AT., Yeap, BY., Mino-Kenudson M, et al. 2009. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. *JClin Oncol.* 2009;27(26):4247-4253.

Shaw, AT., Ou, Sai-Hong.,Bang, Yung-Jue.,Camidge,Ross.,et al. (2014). Crizotinib in ROS1 -Rearranged Non–Small-Cell Lung Cancer. *The New England journal of medicine.* 371. 10.1056/NEJMoa1406766.

Soria, J.C., Massard, C., Chevalier, T.Le., 2010. Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy. *Annals of Oncology* 21: 2324–2332.

Supriadi, K. 2014. Angka Tahan Hidup Pasien Kanker Paru Kelompok Bukan Sel Kecil Non Skuamosa yang mendapat Terapi Target Epidermal Growth Factor Receptor-Tyrosin Kinase Inhibitor dan yang mendapat Kemoterapi Lini Pertama di RS Persahabatan. Diakses melalui <http://lib.ui.ac.id/file?file=digital/2016-5/20417087SPKasum%20Supriadi.pdf> pada tanggal 12 Oktober 2018.

Sutandyo, N., Hanafi, A., & Jayusman, M. 2019. Comparison of Effectiveness of Gefitinib, Erlotinib, and Afatinib in Advanced Non-small Cell Lung Cancer Patients with EGFR Mutation Positive in Indonesian Population. *Zhongguo fei ai za zhi = Chinese journal of lung cancer*, 22(9), 562–567.

Syahrudin, E., Huswatun, A.L., Prabowo, A., Zaini, J., Nurwidya, F., Hudoyo, A., Jusuf, A. 2018.Efficacy of gefitinib and radiotherapy combination in Indonesian patients with lung adenocarcinoma.ROM. J. INTERN. MED., 56, 3, 173–181.

- Tang, E.R., Schreiner, A.M., Pua, B.B.2014. Advances in lung adenocarcinoma classification: a summary of the new international multidisciplinary classification system. *J Thorac Dis*;6(S5):S489-S501.
- Therasse, P., Arbutck, S.G., Eisenhauer, E.A., Wanders, J., Kaplan, R.S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A.T., Christian, M.C., Gwyther, S.G. 2000. New guidelines to evaluate the response to treatment in solid tumors.European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. *J Natl Cancer Inst*.;92:205–16.
- Timmerman, R., Paulus, R., Galvin, J., et al. 2010. Stereotactic Body Radiation Therapy for Inoperable Early Stage Lung Cancer. *JAMA*; 303:1070-1076.
- U.S. Department of Health and Human Services Food and Drug Administration Oncology Center of Excellence Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER).2007. Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics Guidance for Industry.
- Vansteenkiste, J., Crino, L., Doooms, C., et al. 2013. 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up. *Ann Oncol*; 24 (Suppl 6): vi89-vi98.
- Welsh, J. W., Komaki, R., Amini, A., Munsell, M. F., Unger, W., Allen, P. K., *et al.*2013. Phase II trial of erlotinib plus concurrent whole-brain radiationtherapy for patients with brain metastases from non-small-cell lung cancer. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*, 31(7), 895–902.
- Yao, Z.-H., Liao, W.-Y., Ho, C.-C., Chen, K.-Y., Shih, J.-S., Lin, Z.-Z., *et al.*,2017. Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib.*The Oncologist*, 22(2017):1–9.
- Zhang, W., Wei, Y., Yu, D., Xu, J., Peng, J., 2018.Gefitinib provides similar effectiveness and improved safety than erlotinib for advanced non-small cell lung cancer A meta-analysis. *Medicine* 97:16(e0460).
- Zhang, Y., Sheng, J, Kang, S. 2014. Patients with exon 19 deletion were associated with longer progression-free survival compared to those with L858R mutation after first-line EGFR-TKIs for advanced non-small cell lung cancer: a meta analysis. *PLoS one*.;9:1-